

## Special Issue

# Biomarkers of Alpha-Synuclein Pathology

### Message from the Guest Editor

Alpha-synuclein (a-syn) plays a key role in the pathology of Parkinson's disease (PD), dementia with Lewy bodies (DLB), Multiple system atrophy (MSA), and other diseases. However, we are still short of biomarkers for alpha-synuclein pathology and its progression in living people. There are yet no cures for these diseases and biomarkers that can direct future therapies are urgently needed. This special issue aims to gather studies of potential biomarkers of a-syn pathology in PD, DLB, MSA, and related diseases with emphasis on diagnostic and prognostic value, and the use of non-invasive patient samples.

---

### Guest Editor

Dr. Johannes Lange

Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway

---

### Deadline for manuscript submissions

closed (30 June 2023)



## NeuroSci

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.0  
Indexed in PubMed



[mdpi.com/si/79664](https://mdpi.com/si/79664)

*NeuroSci*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[neurosci@mdpi.com](mailto:neurosci@mdpi.com)

[mdpi.com/journal/  
neurosci](https://mdpi.com/journal/neurosci)





# NeuroSci

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.0  
Indexed in PubMed



[mdpi.com/journal/  
neurosci](https://mdpi.com/journal/neurosci)



## About the Journal

### Message from the Editor-in-Chief

*NeuroSci* (ISSN 2673-4087) is an international, peer-reviewed open access journal focusing on neurology and neuroscience. The journal publishes comprehensive reviews, original research papers and high-quality communications. Our aim is to encourage scientists to publish their novel findings and concepts in fundamental and clinical neuroscience as much detail as possible. We invite you to read recent articles published in *NeuroSci* and consider publishing your next paper with us.

---

### Editor-in-Chief

Dr. François Ichas  
Institut des Maladies Neurodégénératives, CNRS et Université de  
Bordeaux, UMR 5293, Bordeaux, France

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within ESCI (Web of Science), PMC, PubMed, EBSCO, and other databases.

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 23.3 days after submission; acceptance to publication is undertaken in 4.7 days (median values for papers published in this journal in the second half of 2025).